A new hormone-free male contraceptive pill, YCT-529, has been found safe in early trials involving 16 healthy men, showing potential as a reversible and side-effect-free option, addressing a significant gap in male contraceptive methods.
A new male contraceptive drug, YCT-529, has successfully passed initial human safety trials, showing no serious side effects and promising reversibility in animal studies, marking a potential breakthrough in non-hormonal, reversible male contraception.
Researchers at Washington State University have discovered a gene in the testes that could lead to the development of a male contraceptive pill. Disabling the gene in mice caused infertility by changing sperm shape and movement. The gene, called ARRDC5, is expressed only in testicular tissue and is abundant in the testes of humans, mice, cattle, and pigs. The discovery could lead to a reversible male contraceptive pill that targets only sperm and has fewer side effects than interfering with male hormones. The researchers have filed a provisional patent for the male contraceptive pill based on this gene discovery.